View : 74 Download: 0
Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy
- Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy
- Lee J.-Y.; Choi Y.-S.; Suh J.-S.; Kwon Y.-M.; Yang V.C.; Lee S.-J.; Chung C.-P.; Park Y.-J.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- International Journal of Cancer
- vol. 128, no. 10, pp. 2470 - 2480
- SCI; SCIE; SCOPUS
- In this study, a cell-penetrating peptide, the transactivating transcriptional factor (TAT) domain from HIV, was linked to a chitosan/doxorubicin (chitosan/DOX) conjugate to form a chitosan/DOX/TAT hybrid. The synthesized chitosan/DOX/TAT conjugate showed a different intracellular distribution pattern from a conjugate without TAT. Unlike both free DOX and the conjugate without TAT, the chitosan/DOX/TAT conjugate was capable of efficient cell entry. The chitosan/DOX/TAT conjugate was found to be highly cytotoxic, with an IC50 value of approximately 480 nM, 2 times less than that of chitosan/DOX (980 nM). The chitosan/DOX/TAT provided decreases in tumor volume of 77.4 and 57.5% compared to free DOX and chitosan/DOX, respectively, in tumor-bearing mice. Therefore, this study suggests that TAT-mediated chitosan/DOX conjugate delivery is effective in slowing tumor growth. Copyright © 2010 UICC.
- Appears in Collections:
- 약학대학 > 약학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.